Publications
Testing Minimum Detectable Activity of Whole-Body Counting System in the Presence of Interfering Factors
The recently updated technical standard for the Department of Energy Laboratory Accreditation Program (DOELAP) may soon require accredited laboratories to empirically verify the estimated minimum detectable activity (MDA) for the nuclides of interest measured by in-vivo detection systems. The Radiation Protection Sample Diagnostics (RPSD) program is the SNL on-site DOELAP accredited laboratory that provides in-vivo measurements of ingested gamma-emitting nuclides (or to prove the lack of significant ingested gamma-emitting nuclides) for the internal dosimetry program administered by Radiation Protection Dosimetry Program (RPDP). Currently, the main nuclides of concern for RPDP include cesium-137 and cobalt-60 as specified in the Statement of Work between the two programs. Historically, MDAs for the RPSD whole-body counting system (WBC) were calculated annually as a-priori values by averaging the critical levels (LC) of any twelve subjects with undetected Co-60 and Cs-137 and assuming MDA is twice the decision level. The purpose of this technical basis document is to evaluate the method and process that validates the a-priori MDA of the RPSD WBC.